Alessandro Corso

Legnano, 20025, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus.

Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus.

Journal: Cancers

Published: June 25, 2026

Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations.

Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations.

Journal: European journal of haematology

Published: September 27, 2025

Targeting CD38 to reduce anti-HLA antibody levels: A new and effective option to be integrated into desensitization protocols?

Targeting CD38 to reduce anti-HLA antibody levels: A new and effective option to be integrated into desensitization protocols?

Journal: Transplant immunology

Published: June 13, 2025

Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework.

Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework.

Journal: BMC cancer

Published: April 17, 2025

An Update of the Appropriate Sequencing for Salvage Therapies in Multiple Myeloma.

An Update of the Appropriate Sequencing for Salvage Therapies in Multiple Myeloma.

Journal: Mediterranean journal of hematology and infectious diseases

Published: March 17, 2025

High-Sensitivity Flow Cytometric Detection of a Small Circulating Population of Nodal T-Follicular Helper Cell Lymphoma Angioimmunoblastic Type Cells.

High-Sensitivity Flow Cytometric Detection of a Small Circulating Population of Nodal T-Follicular Helper Cell Lymphoma Angioimmunoblastic Type Cells.

Journal: Journal of medical cases

Published: February 06, 2025

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.

Journal: Hematological oncology

Published: November 22, 2024

Experts' consensus on the definition and management of high risk multiple myeloma.

Experts' consensus on the definition and management of high risk multiple myeloma.

Journal: Frontiers in oncology

Published: November 12, 2022

Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.

Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.

Journal: Hematological oncology

Published: May 16, 2022

Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel.

Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel.

Journal: Critical reviews in oncology/hematology

Published: October 22, 2021

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.

Journal: Blood advances

Published: July 06, 2021

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.

Journal: European journal of haematology

Published: June 08, 2021

Showing 1-12 of 43

Last Updated: 09/26/2026